July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Pharmaceutical induction of PGC-1α protects retinal pigment epithelium from oxidative stress
Author Affiliations & Notes
  • Magali Saint-Geniez
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Sangeeta Satish
    Boston University School of Medicine, Boston, Massachusetts, United States
  • Hannah Philipose
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Mariana Aparecida Rosales
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
    Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Magali Saint-Geniez, None; Sangeeta Satish, None; Hannah Philipose, None; Mariana Aparecida Rosales, None
  • Footnotes
    Support  The Alcon Young Investigator Award (MSG), The Grimshaw Foundation (MSG), Research to Prevent Blindness Unrestricted Grant (MSG), CNPq Fellowship 210474/2014-9 (MR), NIH National Eye Institute core grant P30EYE003790
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2476. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Magali Saint-Geniez, Sangeeta Satish, Hannah Philipose, Mariana Aparecida Rosales; Pharmaceutical induction of PGC-1α protects retinal pigment epithelium from oxidative stress. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2476.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinal pigment epithelium (RPE) dysfunction due to accumulation of reactive oxygen species and oxidative damage is a key event in the development of age-related macular degeneration (AMD). Our group has previously shown that PGC-1α, a critical regulator of mitochondrial function, promotes RPE oxidative metabolism and that PGC-1α overexpression decreases RPE sensitivity to from AMD-associated pro-oxidants. Here, we examine the therapeutic potential of ZLN005, a selective PGC-1α transcriptional regulator, in protecting RPE from cytotoxic oxidative damage.

Methods : Lentiviral delivery of shRNA specific to human PGC-1α was used to silence its expression in ARPE-19 (shPGC-1a). Non-silencing shRNA was used as the negative control (shControl). LDH assays were used to quantify cell death. Changes in mitochondrial function was measured with the Seahorse extracellular flux analyzer. Quantitative PCR was performed to measure changes in gene expression. Cells were treated with 10mM of ZLN005 for 24 hours. Oxidative stress was induced by exposure to H2O2 (1mM for 18 hours) and NaIO3 (2.5mg/ml for 24 hours) under serum-free conditions.

Results : ZLN005 robustly protects ARPE19 cells from cell death caused by H2O2 (p=1.18x10-5, n=12) and NaIO3 (p=5.27x10-5, n=12) without exhibiting any cytotoxicity under basal conditions (p=0.64, n=24, compared to the vehicle control). Gene expression analysis on ARPE-19 cells treated with ZLN005 shows robust upregulation of PGC-1α (p=0.0004, N=6), its associated anti-oxidant transcription factors (ESSRA, NFE2L2, FOXO3, p < 0.05, n=6), enzymes (CAT p<0.05, GPX1, TXN2 p<0.01 and SOD2 p<0.001, n=6), and mitochondrial dynamics (FIS1 p<0.01, n=6) genes. In addition, energetic profiling shows that ZLN005 treatment also enhances mitochondrial function by increasing maximal respiration (p<0.01, n=4). To demonstrate that ZLN005 protective effects depend on PGC-1α expression, we showed that while ZLN005 treatment protects shControl cells (p=7.16x10-6, n=12) against exposed to H2O2-induced cell death, this effect was loss in PGC1α-silenced cells (p=0.81, n=6).

Conclusions : Our data indicates that ZLN005 efficiently protects RPE cells from oxidative damage through selective induction of PGC-1α and its target anti-oxidant enzymes. ZLN005 may serve as a novel therapeutic agent for retinal diseases associated with RPE dystrophies.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×